The use of Lamivudine-loaded PLGA nanoparticles in the diagnosis of lung cancer: Preparation, characterization, radiolabeling with Tc-99m and cell binding

Creative Commons License

Ekinci M., Öztürk A. A., Santos-Oliveira R., İlem Özdemir D.

JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY, vol.69, 2022 (SCI-Expanded) identifier identifier

  • Publication Type: Article / Article
  • Volume: 69
  • Publication Date: 2022
  • Doi Number: 10.1016/j.jddst.2022.103139
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Biotechnology Research Abstracts, EMBASE
  • Keywords: Lamivudine, Nanoparticles, Technetium-99m, Radiolabeling, Radiopharmaceuticals, Lung cancer diagnosis, CLINICAL-TRIALS, BIODISTRIBUTION
  • Anadolu University Affiliated: Yes


Lung cancer is the leading cause of death (male and female) globally, responsible for over 1.8 million deaths. Although there have been some advances in the treatment of lung cancer, the early detection remains an issue globally. The necessity of new drugs able to efficiently accumulate and image lung cancer is quite required. In this study was developed PLGA nanoparticles loaded with Lamivudine (PLGA-NPs-LAM). The PLGA-NPs-LAM was characterized, radiolabeled with radioactive technetium (Tc-99m), and in vitro evaluated. The results showed a medium size of 203.667 +/- 1.436 nm, with a PDI value of 0.063 +/- 0.052, and a superficial charge of-4.597 +/- 0.368 mV. The entrapment efficacy demonstrated was 48.346 +/- 1.742% of LAM. Radiolabeling of PLGA-NPs-LAM with Technetium-99 m (Tc-99m) showed high efficiency (> 93%). The in vitro assay human lung cancer (A-549) and human fibroblast (L-929) cell lines showed that the NPs were higher uptake in A-549 line than L-929. The data demonstrated that [Tc-99m]Tc-PLGA-NPs-LAM may be a promising agent for lung cancer diagnosis.